• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves another nasal spray for treating opioid overdose

May 23, 2023 By Sean Whooley

Opiant Pharmaceuticals Indivior FDA Opvee opioid overdose nasal spray
Opvee nasal spray. [Image from Indivior/Opiant Pharmaceuticals]
The FDA approved Opvee nalmefene hydrochloride nasal spray for the emergency treatment of opioid overdoses from Opiant Pharmaceuticals.

Approval covers the treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This market the first such authorization for this type of spray in healthcare and community use.

The FDA nod comes on the heels of the March authorization of over-the-counter Narcan. Narcan (naloxone hydrochloride) rapidly reverses the effects of opioid overdose and remains the standard treatment for such an overdose. The nasal spray first received FDA approval in 2015 as a prescription drug.

“The agency continues to advance the FDA Overdose Prevention Framework and take actionable steps that encourage harm reduction by supporting the development of novel overdose reversal products,” said FDA Commissioner Dr. Robert M. Califf. “On the heels of the FDA’s recent approval of the first over-the-counter opioid reversal agent, the availability of nalmefene nasal spray places a new prescription opioid reversal option in the hands of communities, harm reduction groups and emergency responders.”

Indivior acquired Opiant Pharmaceuticals in March of this year. The FDA said it granted approval to Opiant, however.

About Opvee (nalmefene) from Opiant Pharmaceuticals

Namalefene, an opioid receptor antagonist, treats acute opioid overdose. If administered quickly, it can reverse the effects of opioid overdose. That includes respiratory depression, sedation and low blood pressure.

Opiant Pharmaceuticals’ Opvee delivers 2.7 mg of nalmefene into the nasal cavity. It’s available by prescription for use in healthcare and community settings.

According to an FDA news release, Opiant Pharmaceuticals supported this approval with safety and pharmacokinetic studies. It also conducted a study in people who use opioids recreationally to assess how quickly the drug works. Common adverse reactions include nasal discomfort, headache, nausea, dizziness, hot flush, vomiting, anxiety, fatigue, nasal congestion and throat irritation, pain in the nose (rhinalgia), decreased appetite, skin redness (erythema) and excessive sweating (hyperhidrosis).

The FDA granted Opiant Pharmaceuticals a priority review designation. That expedites the development and review of drugs that can potentially provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious condition.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: indivior, opiantpharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS